Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Work
Year: 2011
Type: article
Abstract: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.
Source: New England Journal of Medicine
Authors Paul B. Chapman, Axel Hauschild, Caroline Robert, John B.A.G. Haanen, Paolo A. Ascierto +23 more
Institutions Memorial Sloan Kettering Cancer Center, Kiel University, Institut Gustave Roussy, The Netherlands Cancer Institute, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" +19 more
Cites: 28
Cited by: 7,441
Related to: 10
FWCI: 334.4
Citation percentile (by year/subfield): 100
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze